Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong
Authors:
- Zixuan WangZWZixuan Wang
- Qiuyan YuQYQiuyan Yu
- Julian MatthewmanJMJulian Matthewman
- John TazareJTJohn Tazare
- Sara Benitez MajanoSMSara Benitez Majano
- Jeremy BrownJBJeremy Brown
- Ka Shing CheungKCKa Shing Cheung
- Celine S. L. ChuiCCCeline S. L. Chui
- Esther W. Y. ChanECEsther W. Y. Chan
- Krishnan BhaskaranKBKrishnan Bhaskaran
- Ian C. K. WongIWIan C. K. Wong
- Ian J. DouglasIDIan J. Douglas
- 19 January 2026
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 49 (6) , 677-687
Abstract
Background Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. Objective We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). Methods We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved. Results No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR = 0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30–0.79), ovarian (HR = 0.07, 95% CI 0.01–0.58), and pancreatic (HR = 0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. Conclusions This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.Keywords
Funding Information
- Laboratory of Data Discovery for Health
This publication has 30 references indexed in Scilit:
- Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 YearsJAMA Internal Medicine, 2017
- Triangulation in aetiological epidemiologyInternational Journal of Epidemiology, 2017
- Comparison of Propensity Score Methods and Covariate AdjustmentJACC, 2017
- Best (but oft-forgotten) practices: the multiple problems of multiplicity—whether and how to correct for many statistical testsThe American Journal of Clinical Nutrition, 2015
- Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and MetastasisCancer Research, 2015
- Active-comparator design and new-user design in observational studiesNature Reviews Rheumatology, 2015
- The Microbiome and Obesity—An Established Risk for Certain Types of CancerThe Cancer Journal, 2014
- Cancer risk in long‐term users of vitamin K antagonists: A population‐based case–control studyInternational Journal of Cancer, 2012
- The Association Between Vitamin K Antagonist Therapy and Site-specific Cancer Incidence Estimated by Using Heart Valve Replacement as an Instrumental VariableAmerican Journal of Epidemiology, 2011
- Long-term use of vitamin K antagonists and incidence of cancer: a population-based studyBlood, 2011